Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. was a global generic and specialty pharmaceuticals company founded in 1961 by Milan Puskar and Don Panoz. Before its merger, Mylan's principal executive offices were in Hatfield, UK, with a "Global Center" in Canonsburg, Pennsylvania, U.S. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris Inc. Viatris Inc. is now a public company headquartered in Canonsburg, Pennsylvania, trading on Nasdaq under the ticker VTRS. As of 2024, Viatris reported approximately 32,000 employees and revenues of US$14.7 billion.

The company, as part of Viatris, develops, manufactures, and markets a broad portfolio of medicines, including branded, generic, biosimilar, and over-the-counter (OTC) drugs, as well as active pharmaceutical ingredients (APIs). Its extensive product range covers therapeutic areas such as cardiovascular, infectious disease, oncology, immunology, and central nervous system (CNS) disorders. Historically, Mylan was known for its HIV/AIDS retroviral drugs and the EpiPen auto-injector.

Mylan Pharmaceuticals Inc. has consistently demonstrated the litigation posture of an operating company defending its products. The company has appeared as a defendant in all two of its tracked patent litigation cases and has no recorded appearances as a plaintiff. These cases were heard in the West Virginia Northern District Court and the U.S. Court of Appeals for the Federal Circuit.

A notable legal context for Mylan Pharmaceuticals Inc. involves cases filed by Regeneron Pharmaceuticals, Inc., specifically "Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al." This ongoing litigation is characteristic of patent disputes frequently encountered by pharmaceutical companies regarding their drug formulations and intellectual property.